A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors

We assessed the tolerability and antitumor activity of solitomab, a bispecific T-cell engager (BiTE®) antibody construct targeting epithelial cell adhesion molecule (EpCAM). Patients with relapsed/refractory solid tumors not amenable to standard therapy received solitomab as continuous IV infusion i...

Full description

Bibliographic Details
Main Authors: Maxim Kebenko, Marie-Elisabeth Goebeler, Martin Wolf, Annette Hasenburg, Ruth Seggewiss-Bernhardt, Barbara Ritter, Beate Rautenberg, Djordje Atanackovic, Andrea Kratzer, James B. Rottman, Matthias Friedrich, Eva Vieser, Stefanie Elm, Ingrid Patzak, Dorothea Wessiepe, Sabine Stienen, Walter Fiedler
Format: Article
Language:English
Published: Taylor & Francis Group 2018-08-01
Series:OncoImmunology
Subjects:
amg 110
solitomab
mt110
immunotherapy
bispecific
bite®
epcam, phase 1
solid tumor
cd3
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1450710

Internet

http://dx.doi.org/10.1080/2162402X.2018.1450710

Similar Items